Shinmura Kazuya, Kageyama Shinji, Igarashi Hisaki, Kamo Takaharu, Mochizuki Takahiro, Suzuki Kazuya, Tanahashi Masayuki, Niwa Hiroshi, Ogawa Hiroshi, Sugimura Haruhiko
First Department of Pathology, and.
Exp Ther Med. 2010 Mar;1(2):271-275. doi: 10.3892/etm_00000042. Epub 2010 Mar 1.
EML4-ALK fusion transcripts have been found in a subset of non-small cell lung carcinomas (NSCLCs); however, their protein expression status has not yet been fully elucidated. In this study we investigated ALK protein expression in 302 NSCLCs and 291 gastric carcinomas by means of immunohistochemical analysis. Twelve (4.0%) NSCLCs, but none of the gastric carcinomas, were found to be positive for ALK. The ALK signal was detected in the cytoplasm of cancer cells. Subsequent RNA analysis of 10 RNA-available, immunohistochemically ALK-positive tumors revealed that three tumors had EML4-ALK variant 1, three tumors had variant 2, three tumors had variants 3a and 3b, and one tumor had a novel variant in which exon 14 of EML4 is connected to the nucleotide at position 53 of exon 20 of ALK by a 2-bp insertion. These results suggest that immunohistochemical ALK detection is a useful way to screen NSCLCs for tumors containing ALK fusions.
在一部分非小细胞肺癌(NSCLC)中发现了EML4-ALK融合转录本;然而,它们的蛋白表达状态尚未完全阐明。在本研究中,我们通过免疫组织化学分析调查了302例NSCLC和291例胃癌中的ALK蛋白表达情况。发现12例(4.0%)NSCLC的ALK呈阳性,而所有胃癌的ALK均为阴性。ALK信号在癌细胞的细胞质中被检测到。随后对10例可获得RNA且免疫组化ALK呈阳性的肿瘤进行RNA分析,结果显示,3例肿瘤具有EML4-ALK变异体1,3例肿瘤具有变异体2,3例肿瘤具有变异体3a和3b,1例肿瘤具有一种新的变异体,其中EML4的外显子14通过一个2碱基对的插入与ALK外显子20的第53位核苷酸相连。这些结果表明,免疫组化检测ALK是筛选含有ALK融合的NSCLC肿瘤的一种有用方法。